Panolos Bioscience

Address : Hwaseong-si, Gyeonggi-do, South Korea

Industries : Research

Company Description

Panolos Biosciences is at the forefront of structure-based protein design, ceaselessly pushing the limits of multi-specific drug development. We are dedicated to the creation of anti-angiogenic therapies for the treatment of cancer, autoimmune, and rare diseases. Our unique patented technology, "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific)", employs a VEGF receptor backbone to develop mono or multi-specific antibody therapeutics, amplifying their potency. It is noteworthy that Panolos has now advanced to a clinical-stage company, thanks to the approval of our Phase I clinical trial on May 15, 2023, for our ART-utilized drug PB101, designed to target multiple VEGFs. We are simultaneously making strides in pipeline therapies targeted at PD-L1, EGFR, and TGF-beta(b). Our current partnerships feature a CDMO contract with Samsung Biologics for PB101, and a developmental collaboration with KELUN Biotech for PB203 (PKB01). Please refer to the provided link for further details: https://www.panolos.com/pc/newsroom/newsroom_view.php?idx=224